Tag: Bristol-Myers Squibb Co

Finance

Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb (NYSE:BMY)

During the trial, palbociclib — a pill — was combined with the standard anti-estrogen treatment Letrozole. The combined treatment resulted in a 26.1 month progression-free survival rate compared with only 7.5 months for Letrozole alone. Under development by Pfizer Inc. (NYSE:PFE), the medication used in the study is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Pfizer Inc. (NYSE:PFE) stock performance was -1.06% … Continue reading Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb (NYSE:BMY)

Jayne Crisman
Finance

Healthcare Active runners: Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb Co (NYSE:BMY), Merck & Co (NYSE:MRK), Sanofi (NYSE:SNY)

Israel-based Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) has announced that the U.S. Supreme Court has granted the Company’s Copaxone certiorari petition, and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was 1.39% in last session and finished the day … Continue reading Healthcare Active runners: Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb Co (NYSE:BMY), Merck & Co (NYSE:MRK), Sanofi (NYSE:SNY)

Mark DeFrance
Finance

Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb (NYSE:BMY)

Three years after Pfizer Inc. (NYSE:PFE) announced more than 1,000 layoffs that Gov. Dannel P. Malloy at the time called “terrible news,” the pharmaceutical company and the state said Wednesday they’ve come up with new uses for the Groton site. Malloy and top officials of his administration and Pfizer Inc (NYSE:PFE) said two vacant buildings on the company’s campus will be used for bioscience research … Continue reading Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb (NYSE:BMY)

Jayne Crisman
FB Nasdaq FB Facebook
Diversified Tech

Healthcare Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Bristol-Myers Squib (NYSE:BMY), Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Congress jumped into the health care game (again) by “complaining” that Gilead Sciences, Inc. (NASDAQ:GILD)’s hepatitis drug was priced too high. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.92% in last session and finished the day at $73.64. Traded volume was 19.50million shares in the last session and the average volume of the stock remained 13.29million shares. The beta of the stock remained 0.55. Gilead … Continue reading Healthcare Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Bristol-Myers Squib (NYSE:BMY), Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Jason Knox
Finance

Healthcare active runners: Galena Biopharma Inc (NASDAQ:GALE), Bristol-Myers Squibb (NYSE:BMY), Idera Pharmaceuticals Inc (NASDAQ:IDRA), EXACT Sciences Corporation (NASDAQ:EXAS)

Trade-Ideas LLC identified Galena Biopharma Inc (NASDAQ:GALE) as a “dead cat bounce” (down big yesterday but up big today) candidate. TheStreet Quant Ratings rates Galena Biopharma Inc (NASDAQ:GALE) as a sell. Galena Biopharma Inc (NASDAQ:GALE) stock performance was 12.61% in last session and finished the day at $2.50. Traded volume was 6.16million shares in the last session and the average volume of the stock remained … Continue reading Healthcare active runners: Galena Biopharma Inc (NASDAQ:GALE), Bristol-Myers Squibb (NYSE:BMY), Idera Pharmaceuticals Inc (NASDAQ:IDRA), EXACT Sciences Corporation (NASDAQ:EXAS)

John Bellich
Finance

Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE) announced that PROFILE 1014, a phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) when compared to standard platinum-based chemotherapy regimens. Pfizer Inc. (NYSE:PFE) stock performance was 1.13% in last session and finished the day at $32.18. … Continue reading Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis